Placebo News and Research

RSS

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression.

31 Mar 2014

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

31 Mar 2014

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

29 Mar 2014

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

28 Mar 2014

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC.

28 Mar 2014

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose.

27 Mar 2014

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections.

26 Mar 2014

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

26 Mar 2014

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

United Therapeutics Corporation today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration.

26 Mar 2014

Cogstate's cognition test to play key role in A4 trial for Alzheimer’s disease

Cognition testing technology developed by Cogstate will be used to track the neurological health of elderly people involved in the multinational Phase III clinical trial of a promising new Alzheimer’s disease (AD) drug.

26 Mar 2014

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia.

25 Mar 2014

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

25 Mar 2014

Anxiety relief in children: an interview with Dr. Golda Ginsburg, Johns Hopkins Children’s Center

Anxiety is the most common psychiatric disorder among youth. Prevalence rates hover around 10%, although the actual percent varies depending on the specific anxiety disorder, sample, method of assessment, etc.

24 Mar 2014

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

24 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

24 Mar 2014

New weapon against secondary progressive MS

Statins may provide doctors with an unlikely new weapon with which to slow the progression of multiple sclerosis (MS).

20 Mar 2014

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.

20 Mar 2014

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Université Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders.

20 Mar 2014

Placebo News and Research

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

Cogstate's cognition test to play key role in A4 trial for Alzheimer’s disease

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Anxiety relief in children: an interview with Dr. Golda Ginsburg, Johns Hopkins Children’s Center

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

FDA approves Xolair for treatment of chronic idiopathic urticaria

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

New weapon against secondary progressive MS

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News